Webinar
15 Nov 2022

Indena's Commitment to Sustainability: From Responsible Supply Chain Management to Smart Use of Energy, we aim to Protect Nature, People, and Business

Indena is relentlessly working to generate a sustainable impact on its stakeholders, cultivating with care its own precious circle: Nature, Technology, and People. In terms of actual projects and actions, Indena's commitment in sustainability includes responsible supply chain management, a circular economy in product design, and very smart use of energy in its plants. As for energy use, which is linked to climate change, one of the most urgent global sustainability challenges, Indena has been working for years to reduce consumption, save energy, and achieve high levels of energy self-production. All the actions taken for sustainability allow Indena to be fully reliable in terms of business continuity and thus be a solid partner for all its clients.

Content provided by our supplier

Indena S.P.A

  • IT
  • 2015
    On CPHI since
  • 5
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Nutraceuticals

Other Content from Indena S.P.A (3)

  • Video From the Rainforest to the Clinic. Turning a High-Potency Rare Natural Product Into an Anticancer API

    Natural products can be characterized by complex structure, limited availability, and exceptional potency, whose combination makes it challenging their development as API. Success requires integration of expertise in different areas, including the construction of a sustainable supply chain for the starting biomass, the capacity to manipulate high-potency products in a GMP environment, and the versatility to strategically complement isolation with semi-synthesis, total synthesis and biotechnology. In this context, mutual thrust between the service provider company and the drug candidate owner is critical, and the successful development of the anticancer drug tigilanol tiglate will give the opportunity to address these issues.
  • Whitepaper CDMO services

    We have a unique expertise in developing and manufacturing HPAPIs. The company is equipped with kilolabs (for clinical and small commercial batches) and large industrial suite for HPAPIs with an OEL>20 ng/m3.